Gene expression identifies patients who develop inflammatory arthritis in a clinically suspect arthralgia cohort

Journal Article (2020)
Author(s)

Ellis Niemantsverdriet (Leiden University Medical Center)

Erik B. van den Akker (TU Delft - Pattern Recognition and Bioinformatics, Leiden University Medical Center)

Debbie M. Boeters (Leiden University Medical Center)

Susan J.F. van den Eeden (Leiden University Medical Center)

Annemieke Geluk (Leiden University Medical Center)

Annette H.M. van der Helm-van Mil (Erasmus MC, Leiden University Medical Center)

Research Group
Pattern Recognition and Bioinformatics
DOI related publication
https://doi.org/10.1186/s13075-020-02361-2
More Info
expand_more
Publication Year
2020
Language
English
Research Group
Pattern Recognition and Bioinformatics
Issue number
1
Volume number
22
Reuse Rights

Other than for strictly personal use, it is not permitted to download, forward or distribute the text or part of it, without the consent of the author(s) and/or copyright holder(s), unless the work is under an open content license such as Creative Commons.

Abstract

Background: Established rheumatoid arthritis (RA) patients display differentially expressed genes coding for cytokine/chemokine-mediated immunity compared to healthy controls. It is unclear, however, if in the pre-arthritis phase of clinically suspect arthralgia (CSA) expression of immune genes differ between patients who do or do not develop clinically evident inflammatory arthritis (IA). Methods: Two hundred thirty-six consecutive patients presenting with arthralgia clinically suspected for progression to RA were followed until IA development or else for median 24 months (IQR 12–26). Baseline whole blood RNA expression was determined for a previously identified set of 133 genes associated with the innate and adaptive immune system by dual-color reverse-transcription multiplex ligation-dependent probe amplification (dcRT-MLPA) profiling. Cox proportional hazard models were used. Results: Twenty percent of CSA patients developed IA. After correction for multiple testing, expression levels of six genes (IFNG, PHEX, IGF-1, IL-7R, CD19, CCR7) at the time of presentation were associated with progression to IA. PHEX and IGF-1 were highly correlated with each other (ρ = 0.97). In multivariable analysis correcting for the different genes, expressions of IL-7R and IGF-1 were independently associated with IA development (p = 0.025, p = 0.046, respectively). Moreover, IL-7R and IGF-1 remained significantly associated even after correction for known predictors (ACPA, CRP, imaging-detected subclinical joint inflammation; p = 0.039, p = 0.005, respectively). These genes are also associated with RA development. Conclusions: IL-7R and IGF-1 were differentially expressed between CSA patients who did or did not progress to IA, independent from regularly used predictors. These biomarkers may become helpful in prognostication of CSA patients. Furthermore, because both genes are associated with T cell functioning, T cell dysregulation may mediate progression from arthralgia to arthritis.